High-dose (HD) bolus IL-2 therapy is one of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond ...
via Medindia Health News
More READ 
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/12/how-to-predict-outcome-for-high-dose-il.html
No comments:
Post a Comment